Led · Seed · Jan 2026

Clearcut Surgical develops a multifunctional surgical device designed to consolidate several operative tasks into one instrument, aiming to streamline procedures and improve surgical efficiency. The company positions its product for operating rooms that seek to reduce instrument swaps and associated procedure times. Details on commercial traction, revenue, or user adoption have not been disclosed, but Angel Investor Forum’s criteria suggest the product is at or near market readiness. Clearcut Surgical’s recent capital infusion indicates it is still in an early stage, likely focusing on product refinement, regulatory clearances, and initial market entry. The firm operates from Boston and now gains the backing of over 100 accredited investors within AIF’s network, potentially providing strategic healthcare expertise alongside funding.

Participated · Equity · Feb 2024

DeepLook Medical’s flagship product, DL Precise™, is an AI-powered software that uses shape-recognition algorithms to visualize, measure, and segment abnormal growths in dense breast tissue. The company positions DL Precise™ as a tool to improve accuracy in detecting and assessing suspicious lesions, with the potential to enhance early cancer detection and patient outcomes. DeepLook says its technology is the first in a series of products built on its unique shape-recognition software and leveraged alongside complementary AI advances and patented technology. The company plans to use newly raised capital to further commercialize its technology with current and new partners, explore applications in additional imaging modalities, and broaden its global presence. DeepLook emphasizes improving physician diagnosis and treatment decisions across oncology through clearer tumor morphology delineation. The press release highlights Xcellerant’s support and strategic involvement as part of its commercialization efforts. DeepLook Medical, led by CEO Marissa Fayer and based in New Haven, Connecticut, develops AI software to improve visualization of suspicious masses in dense breasts. Its flagship product, DL Precise, is an FDA-cleared shape-recognition platform that overlays onto existing imaging screens to provide one-click measurement, segmentation, and visualization. DL Precise delineates tumor morphology using a single-click deterministic algorithm and is compatible with mammography, ultrasound, CT, and MRI. The product has entered the commercial market through partnerships with Barco, Blackford, Tempus, and Radical Imaging. DeepLook plans to use the $1.7M funding to hire talent, advance next-generation products, expand sales and partnerships, support additional clinical research and publications, and extend global IP and regulatory protections and clearances. The company is also leveraging complementary AI advances to enhance the reach and impact of its patented technology.

Participated · Seed · Jun 2017

Lynq developed the human compass, a device that uses GPS to enable private, peer-to-peer location and data tracking without cellular networks or infrastructure. Its core technology is a licensable software and network protocol that can be integrated into other devices to enable decentralized device-to-device communication of location, messages, sensor and other low-bandwidth data over miles. The company currently sells its people compass direct-to-consumer and to government customers, which were the primary sources of 2020 revenue. Lynq also completed a $1.7M presale that helped drive early interest and investor traction. Management says licensing the software will evolve into its primary, high-margin and scalable revenue stream, shifting focus from device sales. Near-term plans include growing the team, completing software development, announcing integrations and partnerships, and beginning integration of the technology into licensee devices while continuing device sales. Lynq makes peer-to-peer location devices that let individuals and groups locate each other anywhere, independent of phones, cellular networks, Wi‑Fi and maps. Its rugged, waterproof hardware supports up to 40,000 units in a small area without interference. The company plans a B2B2C rental rollout followed by direct-to-consumer sales targeting families and outdoor enthusiasts, and also aims for government customers. Successful betas were conducted at Telluride and other ski resorts, and additional tests are scheduled at theme parks and festivals. The technology is under evaluation for use in disaster relief, search and rescue, and stealth operations. Lynq was founded in October 2014, is an alumnus of the HAX hardware accelerator, and is led by CEO Dave Shor.

Participated · Equity · Jan 2015

Device42 is a New Haven, Conn.-based provider of software that automatically and agentlessly discovers entire IT infrastructure and maps application dependencies. Led by CEO Raj Jalan, the company's platform gives comprehensive and current insight into any computing environment. Device42 serves customers in more than 60 countries, including Global 2000 clients and systems integrators. On July 3, 2019, Device42 raised $34M in funding; the backers were not disclosed. In connection with the transaction, Dan Phillips (former CEO and Chairman of CloudHealth Technologies) and Darren Battistoni (Managing Director at Charlesbank Capital Partners) joined Device42’s board of directors. The company intends to use the funds to continue to grow its solutions. Device42 is a New Haven, Conn.-based provider of datacenter infrastructure management solutions. The company offers high-end DCIM software to large and small customers worldwide. Its software is delivered as a virtual appliance and provides forms, spreadsheets, distributed auto-discovery, and RESTful APIs for data input and application integration. The product includes advanced visualizations of rooms, racks, connections, wiring, and dependencies. Device42 is led by CEO Raj Jalan and CTO Dr. Steve Shwartz. The company recently raised $3.505M and intends to use the funds to further expand the business and operations.

Participated · Equity · Jun 2014

ZetrOZ develops miniature wearable ultrasound devices, including sam® (sustained acoustic medicine) and UltrOZ®, for accelerated recovery and pain management. The sam® device targets non-pharmaceutical, bio-regenerative alternatives within the roughly $62 billion U.S. pain management market. Early adopters of sam® include physical therapists, athletic trainers and athletes using it for overuse injuries such as tendonopathies and muscle strains. UltrOZ™ Elite with OZ Inside™ launched in mid-2011 for equestrian rehabilitation to treat common musculoskeletal conditions in horses. The company is led by co-founder and CEO Bryant Guffey and Chief Scientific and Technology Officer Dr. George K. Lewis. ZetrOZ received a $5M venture loan facility which it plans to use to expand marketing and sales of its wearable ultrasound products beyond the professional market and into the consumer arena. ZetrOZ develops Sam, an iPod-sized wearable that delivers ultrasound therapy through a patch to treat musculoskeletal and joint pain and to improve circulation. Sam is designed to be worn for four hours at a time and is described by the company as a sustained acoustic medicine device. The company secured FDA 510(k) clearance for Sam a few months before the raise. ZetrOZ has raised a little more than $2 million from angel groups and private investors, according to a Form D filed with the SEC. Named backers include Connecticut Innovations, Standard Oil Ventures, Angel Investor Forum, Mass Medical Angels, Boston Harbor Angels and Launchpad Venture Group. The funds are likely to be used to support sales, marketing and manufacturing, and the company says it will focus on educating the medical community and patients about its drug-free pain solution. The company was started by a pair of Cornell grads; co-founders include CEO Brant Guffey, CSO George Lewis and COO JoAnne Guarino. Prior to Sam, ZetrOZ launched an ultrasound therapy product for horses called UltrOZ in 2011. ZetrOZ has developed a small portable/wearable ultrasound system designed to treat pain in humans and animals. The patent-pending device delivers low-intensity, long-duration ultrasound therapy and is intended for use while patients sleep, move, or receive care in a doctor’s or physical therapist’s office. The system consists of a battery pack, transducers that provide the therapy, and disposable hydrogel patches that attach the transducers to the patient’s body. The product will be available for purchase by doctors and physical therapists and for patients to self-administer therapy. The company also markets UltrOZ, a system for the equine market designed to treat pain and reduce the need for invasive therapies. ZetrOZ is based in Trumbull, Connecticut and currently has a staff of 12.